Neuland Laboratories Overview
- Year Founded
-
1984
- Status
-
Public
- Employees
-
2,855
- Stock Symbol
-
524558
- Investments
-
2
- Share Price
-
$138.87
- (As of Thursday Closing)
Neuland Laboratories General Information
Description
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
Contact Information
Website
www.neulandlabs.comCorporate Office
- 11th Floor (5th Level), Phoenix IVY Building
- Plot Number. 573A-III, Road Number. 82, Jubilee Hills
- Hyderabad, 500033
- India
Corporate Office
- 11th Floor (5th Level), Phoenix IVY Building
- Plot Number. 573A-III, Road Number. 82, Jubilee Hills
- Hyderabad, 500033
- India
Neuland Laboratories Stock Performance
As of 10-Jul-2025, Neuland Laboratories’s stock price is $138.87. Its current market cap is $1.78B with 12.8M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $138.87 | $139.67 | $94.08 - $213.61 | $1.78B | 12.8M | 3.19K | $2.40 |
Neuland Laboratories Financials Summary
As of 31-Mar-2025, Neuland Laboratories has a trailing 12-month revenue of $170M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 | FY 2023 31-Mar-2023 |
|---|---|---|---|---|
| EV | 1,800,887 | 1,800,887 | 961,463 | 303,318 |
| Revenue | 169,641 | 169,641 | 183,082 | 144,574 |
| EBITDA | 48,145 | 48,145 | 56,046 | 34,543 |
| Net Income | 30,762 | 30,762 | 36,248 | 20,364 |
| Total Assets | 254,840 | 254,840 | 219,749 | 192,417 |
| Total Debt | 18,370 | 18,370 | 11,438 | 15,645 |
Neuland Laboratories Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Neuland Laboratories Comparisons
Industry
Financing
Details
Neuland Laboratories Competitors (14)
One of Neuland Laboratories’s 14 competitors is Mankind Pharma, a Formerly PE-Backed company based in New Delhi, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mankind Pharma | Formerly PE-Backed | New Delhi, India | ||||
| Granules India | Corporation | Hyderabad, India | ||||
| Natco Pharma | Corporation | Hyderabad, India | ||||
| Laborate Pharmaceuticals India | Corporation | Panipat, India | ||||
| Cipla | Corporation | Mumbai, India |
Neuland Laboratories Patents
Neuland Laboratories Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4146249-A1 | Improved process for the preparation of semaglutide | Inactive | 05-May-2020 | ||
| EP-4146249-A4 | Improved process for the preparation of semaglutide | Inactive | 05-May-2020 | ||
| US-20230220036-A1 | Improved process for the preparation of semaglutide | Pending | 05-May-2020 | ||
| US-20230108536-A1 | Methods of preparing chiral benzodiazepinone derivatives | Pending | 16-Feb-2020 | ||
| EP-2956486-A1 | An improved process for preparation of sugammadex sodium | Active | 14-Feb-2013 | C08B37/0012 |
Neuland Laboratories Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Neuland Laboratories Investments & Acquisitions (2)
Neuland Laboratories’s most recent deal was a Corporate Asset Purchase with Arch Pharmalabs (Hyderabad Facility). The deal was made on 13-Dec-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Arch Pharmalabs (Hyderabad Facility) | 13-Dec-2017 | Corporate Asset Purchase | Buildings and Property | ||
| Neuland Health Sciences | 08-Nov-2016 | Merger/Acquisition | Holding Companies |
Neuland Laboratories ESG
Risk Overview
Risk Rating
Updated January, 18, 2025
26.4 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,697
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Pharmaceuticals
Subindustry
of 420
Rank
Percentile
Neuland Laboratories Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Neuland Health Sciences | Hyderabad, India | 1993 |
Neuland Laboratories FAQs
-
When was Neuland Laboratories founded?
Neuland Laboratories was founded in 1984.
-
Where is Neuland Laboratories headquartered?
Neuland Laboratories is headquartered in Hyderabad, India.
-
What is the size of Neuland Laboratories?
Neuland Laboratories has 2,855 total employees.
-
What industry is Neuland Laboratories in?
Neuland Laboratories’s primary industry is Pharmaceuticals.
-
Is Neuland Laboratories a private or public company?
Neuland Laboratories is a Public company.
-
What is Neuland Laboratories’s stock symbol?
The ticker symbol for Neuland Laboratories is 524558.
-
What is the current stock price of Neuland Laboratories?
As of 10-Jul-2025 the stock price of Neuland Laboratories is $138.87.
-
What is the current market cap of Neuland Laboratories?
The current market capitalization of Neuland Laboratories is $1.78B.
-
What is Neuland Laboratories’s current revenue?
The trailing twelve month revenue for Neuland Laboratories is $170M.
-
Who are Neuland Laboratories’s competitors?
Mankind Pharma, Granules India, Natco Pharma, Laborate Pharmaceuticals India, and Cipla are some of the 14 competitors of Neuland Laboratories.
-
What is Neuland Laboratories’s annual earnings per share (EPS)?
Neuland Laboratories’s EPS for 12 months was $2.40.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
